WallStSmart

ResMed Inc (RMD)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ResMed Inc generates 66% more annual revenue ($5.54B vs $3.33B). RMD leads profitability with a 27.4% profit margin vs 17.0%. RMD appears more attractively valued with a PEG of 1.26. RMD earns a higher WallStSmart Score of 73/100 (B).

RMD

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 9.0Value: 4.7Quality: 9.5
Piotroski: 6/9Altman Z: 4.34

WST

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RMDSignificantly Overvalued (-27.2%)

Margin of Safety

-27.2%

Fair Value

$204.13

Current Price

$223.14

$19.01 premium

UndervaluedFair: $204.13Overvalued
WSTSignificantly Overvalued (-47.9%)

Margin of Safety

-47.9%

Fair Value

$166.45

Current Price

$348.76

$182.31 premium

UndervaluedFair: $166.45Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RMD5 strengths · Avg: 9.4/10
Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
23.4%9/10

Every $100 of equity generates 23 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

Debt/EquityHealth
0.139/10

Conservative balance sheet, low leverage

WST3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Operating MarginProfitability
22.5%8/10

Strong operational efficiency at 22.5%

Areas to Watch

RMD0 concerns · Avg: 0/10

No major concerns identified

WST3 concerns · Avg: 2.7/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

PEG RatioValuation
2.912/10

Expensive relative to growth rate

P/E RatioValuation
43.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Bear Case : WST

The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.

Key Dynamics to Monitor

WST carries more volatility with a beta of 1.16 — expect wider price swings.

WST is growing revenue faster at 13.8% — sustainability is the question.

RMD generates stronger free cash flow (520M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RMD scores higher overall (73/100 vs 61/100), backed by strong 27.4% margins and 10.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?